← SynDRA
GEFITINIB
SynDRA canonical compound SYN0002694 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- EGFR
- ABCB1
- PRKD1
- PIM3
- PHKG2
- PHKG1
- NUAK2
- NLK
- MYLK2
- MKNK2
- MKNK1
- MINK1
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NOD1
- HRH3
- ESR1
- ABCC4
- YES1
- BRSK1
- KCNH2
- SYK
- NOD2
- PIM1
- LIMK1
- DRD2
- PBK
- PDE3A
- AAK1
- PDE4D
- PDGFRA
- PAK6
- PDGFRB
- PDPK1
- PASK
- PAK3
- PAK5
- PAK4
- PEBP1
- PAK2
- PAK1
- PAICS
- OXSR1
- OPRM1
- OPRK1
- OPRD1
- OPA1
- OLA1
- PDXK
- PIK3C2B
- PFKP
- PKN1
- PRKAG1
- PRKACG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- AHR
- ANDR
- KSYK
- M4K4
- M4K5
- MAP1LC3B
- MK06
- MK09
- MK10
- MK14
- NF2L2
- NNMT
- NSD2
- NTM1A
- NTMT1
- PNMT
- PRGR
- RARA
- SMAD2
- SMAD3
- ST17A
- KPCD3
- KPCD2
- KCC2G
- ESR2
- ATXN2
- CASP3
- CASP7
- COMT
- CP2CJ
- CP2D6
- CP3A7
- CTRO
- ESRRA
- KCC2D
- GAMT
- GEMI
- GLI3
- GNMT
- GPR32
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- IRESSA
- Iressa
- ZD1839
- iressa
- ZD 1839
- NSC-759856
- ZD-1839
- Gefitinib mylan
- Gefitini
- IRE
- Irressat
- Gefitinib [USAN]
- Iressa (TN)
- Iressa(TM)
- CU-00000000396-1
- Gefitinib,Iressa, ZD1839
- Gefitinib (JAN/USAN/INN)
- ZD-1839, Iressa, Gefitinib
- 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
- gefitinib (zd1839)
- Gefitinib (GMP)
- MFCD04307832
- CHEMBL939
- NSC 759856
- S65743JHBS
- CHEBI:49668
- NCGC00159455-02
- CCRIS 9011
- CAS-184475-35-2
- SR-00000000262
- gefitinibum
- UNII-S65743JHBS
- Gefitinib [USAN:INN:BAN]
- Gefitini; Iressa
- gefitinib (iressa)
- Gefitinib - Iressa
- Iressa (AstraZeneca)
Reported adverse events
- Conjunctivitis
- Keratitis
- Proteinuria
- Skin reaction
- Stomatitis
- Vomiting
- Nail disorder
- Acne
- Acne pustular
- Alanine aminotransferase increased
- Aspartate aminotransferase increased
- Blepharitis
Look up GEFITINIB in the interactive SynDRA portal →